Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker

다국어 초록 (Multilingual Abstract)

Purpose: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC).
Materials and Methods: Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients and controls.
Results: RCC patients had higher serum PHD3 levels than controls (0.79±0.17 ng/mL vs. 0.73±0.09 ng/mL, p=0.023), with an area under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, respectively. No significant difference in PHD3 level was observed between healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respectively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 months were significantly lower than the preoperative PHD3 levels (both p<0.001).
Conclusions: Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.

참고문헌 (Reference)

1 Leroy X, "Vascular endocan(ESM-1)is markedly overexpressed in clear cell renal cell carcinoma" 56 : 180-187, 2010

2 Amatschek S, "Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes" 64 : 844-856, 2004

3 Jokilehto T, "The role of HIF prolyl hydroxylases in tumour growth" 14 : 758-770, 2010

4 Fox SB, "The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen" 13 : R16-, 2011

5 Cerami E, "The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data" 2 : 401-404, 2012

6 Dong D, "Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma" 35 : 279-285, 2017

7 Xue J, "Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity" 138 : 606-615, 2010

8 Cui L, "Prolyl hydroxylase 3 inhibited the tumorigenecity of gastric cancer cells" 53 : 736-743, 2014

9 Ambani SN, "Predictors of delayed intervention for patients on active surveillance for small renal masses : does renal mass biopsy influence our decision" 98 : 88-96, 2016

10 Su Y, "PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer" 103 : 1571-1579, 2010

11 Schofield CJ, "Oxygen sensing by HIF hydroxylases" 5 : 343-354, 2004

12 Andersen S, "Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival" 6 : e23847-, 2011

13 Weiss RH, "Kidney cancer : identification of novel targets for therapy" 69 : 224-232, 2006

14 Sato E, "Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma" 14 : 6916-6923, 2008

15 Tanaka T, "Hypoxia-inducible factor(HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma" 140 : 503-513, 2014

16 Schödel J, "Hypoxia, hypoxia-inducible transcription factors, and renal cancer" 69 : 646-657, 2016

17 Ivan M, "HIFalpha targeted for VHL-mediated destruction by proline hydroxylation : implications for O2 sensing" 292 : 464-468, 2001

18 Miikkulainen P, "HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma" 5 : 5-, 2017

19 Isaacs JS, "HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer : novel role of fumarate in regulation of HIF stability" 8 : 143-153, 2005

20 Mole DR, "Genome-wide association of hypoxia-inducible factor(HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts" 284 : 16767-16775, 2009

21 Gossage L, "Expression of key hypoxia sensing prolyl-hydroxylases PHD1, -2 and-3 in pancreaticobiliary cancer" 56 : 908-920, 2010

22 Morrissey JJ, "Evaluation of urine aquaporin-1 and perilipin-2 concentrations as biomarkers to screen for renal cell carcinoma : a prospective cohort study" 1 : 204-212, 2015

23 Go AS, "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization" 351 : 1296-1305, 2004

24 Stillebroer AB, "Carbonic anhydrase IX in renal cell carcinoma : implications for prognosis, diagnosis, and therapy" 58 : 75-83, 2010

25 Tanaka T, "Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma" 137 : 789-794, 2011